Brokers Set Expectations for Genelux Co.’s FY2028 Earnings (NASDAQ:GNLX)

Genelux Co. (NASDAQ:GNLXFree Report) – Research analysts at HC Wainwright issued their FY2028 EPS estimates for shares of Genelux in a research report issued to clients and investors on Tuesday, April 2nd. HC Wainwright analyst E. Bodnar expects that the company will earn $0.82 per share for the year. HC Wainwright has a “Buy” rating and a $32.00 price target on the stock. The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share.

Genelux Stock Performance

Shares of GNLX stock opened at $5.25 on Wednesday. The company’s 50-day simple moving average is $7.62 and its two-hundred day simple moving average is $13.25. Genelux has a one year low of $4.89 and a one year high of $40.98.

Hedge Funds Weigh In On Genelux

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Woodward Diversified Capital LLC raised its holdings in shares of Genelux by 2,326.2% in the fourth quarter. Woodward Diversified Capital LLC now owns 1,082,270 shares of the company’s stock worth $15,163,000 after buying an additional 1,037,663 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Genelux by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 998,810 shares of the company’s stock worth $13,993,000 after buying an additional 17,817 shares during the last quarter. Provident Wealth Management LLC purchased a new position in shares of Genelux in the third quarter worth $8,211,000. AE Wealth Management LLC raised its holdings in shares of Genelux by 1,370.0% in the third quarter. AE Wealth Management LLC now owns 194,875 shares of the company’s stock worth $4,772,000 after buying an additional 181,618 shares during the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Genelux by 2.0% in the fourth quarter. Northern Trust Corp now owns 164,083 shares of the company’s stock worth $2,299,000 after buying an additional 3,267 shares during the last quarter. 37.33% of the stock is currently owned by institutional investors.

About Genelux

(Get Free Report)

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.

Further Reading

Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.